Ignite Creation Date:
2024-05-06 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 2:31 PM
Study NCT ID:
NCT05346224
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-16
First Post:
2022-04-17
Brief Title:
A Study to Evaluate the Efficacy and Safety of HLX11 vs EU-Perjeta in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
Sponsor:
Shanghai Henlius Biotech
Organization:
Shanghai Henlius Biotech
Organization Data
Organization:
Shanghai Henlius Biotech
Class:
INDUSTRY
Study ID:
HLX11-BC301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai Henlius Biotech
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None